```html

Usnea (Lichen) – Comprehensive Medical Guide

Overview

Usnea, commonly called “old‑man's beard,” is a fruticose (shrubby) lichen that grows on trees, rocks, and sometimes on soil in moist, temperate climates. While most people encounter Usnea as a harmless component of the natural environment, it can cause health problems when fragments become airborne or come into direct contact with the skin, eyes, or respiratory tract.

Usnea is not a disease of the human body itself; rather, it is a fungal‑algal symbiotic organism that can act as an irritant or allergen. When the term “Usnea (lichen) infection” is used in medical literature, it usually refers to an allergic, irritant, or toxic reaction to the lichen’s secondary metabolites (e.g., usnic acid).

• Who it affects: Anyone exposed to high concentrations of Usnea spores or thallus fragments, but outdoor workers, hikers, forest‑rangers, and people living in humid, forested regions are most at risk.
• Prevalence: Precise epidemiologic data are limited because reactions are often under‑reported. A 2020 review of environmental allergies in the United States estimated that lichen‑related contact dermatitis accounts for <≈1–2 % of all contact dermatitis cases <sup>1</sup>. In high‑altitude, temperate zones of Europe and North America, Usnea can be present on <≈10 % of mature coniferous trees<sup>2</sup>, increasing exposure potential.
• Seasonality: Growth peaks in late spring through early autumn when humidity and temperature are optimal (10‑25 °C).

Symptoms

Symptoms vary according to the route of exposure—skin, eyes, or respiratory tract. Below is a complete list with descriptions:

Cutaneous (Skin) Manifestations

• Contact dermatitis: Red, itchy rash that may become vesicular (blister‑like) or weepy. Usually appears 12‑48 hours after direct contact.
• Photosensitive dermatitis: Rash that worsens after sun exposure; Usnic acid can act as a photosensitizer.
• Hyperpigmentation: Darkened patches that persist after the acute inflammation resolves.
• Secondary infection: Scratching can introduce bacteria, leading to cellulitis or impetigo.

Ocular (Eye) Manifestations

• Conjunctivitis: Red, gritty eyes with tearing and a burning sensation.
• Keratitis: Rare but possible if fragments embed in the cornea, causing pain, photophobia, and blurred vision.

Respiratory Manifestations

• Upper‑airway irritation: Sore throat, hoarseness, or a dry cough after inhaling spores.
• Asthmatic exacerbation: In susceptible individuals, Usnea can trigger bronchospasm, wheezing, and shortness of breath.
• Allergic rhinitis‑like symptoms: Nasal congestion, itching, and sneezing.
• Hypersensitivity pneumonitis (rare): Fever, chills, dyspnea, and diffuse lung infiltrates after prolonged high‑level exposure (e.g., occupational).

Systemic Effects (Very Rare)

• Gastrointestinal irritation if ingested accidentally (e.g., children chewing on lichen).
• Liver enzyme elevation reported in a handful of case reports after chronic high‑dose usnic‑acid supplementation (outside normal environmental exposure) <sup>3</sup>.

Causes and Risk Factors

Usnea does not “cause” disease in the classic infectious sense. The health issues stem from:

• Allergic sensitization: Immune system recognizes usnic acid or other lichen compounds as foreign, producing IgE‑mediated reactions.
• Irritant contact: Direct physical irritation from the lichen’s fruticose thallus or its acidic metabolites.
• Phototoxicity: Usnic acid absorbs UV‑A radiation, generating reactive oxygen species that damage skin cells.

Key Risk Factors

• Occupations with frequent forest exposure (forestry workers, park rangers, landscapers).
• Recreational activities in humid, lichen‑rich environments (hiking, mushroom foraging).
• Pre‑existing atopic dermatitis, asthma, or allergic rhinitis.
• Use of herbal supplements containing usnic acid (some “natural” weight‑loss or anti‑bacterial products).
• Compromised skin barrier (e.g., cuts, eczema) that permits deeper penetration.

Diagnosis

Because Usnea‑related reactions mimic many other dermatologic or respiratory conditions, a systematic approach is essential.

Clinical Evaluation

1. History: Detailed exposure assessment—recent hikes, work in forested areas, use of topical/herbal products, and timing of symptom onset.
2. Physical exam: Distribution of rash (often linear or in areas of contact), presence of lichen fragments on skin/clothing, eye examination, and respiratory assessment.

Diagnostic Tests

• Patch testing: Standardized allergens that include usnic acid are applied to the back for 48 hours. A positive reaction confirms contact allergy (American Contact Dermatitis Society recommends this for suspected lichen dermatitis).
• Skin prick testing: Less common for lichens but may be used if systemic allergy suspected.
• Scraping or biopsy: In persistent or atypical lesions, a skin biopsy can rule out infection or psoriasis. Histology typically shows spongiotic dermatitis with eosinophils.
• Ophthalmic slit‑lamp exam: For eye involvement, to detect corneal abrasions or conjunctival inflammation.
• Pulmonary function tests (PFTs): If asthma or hypersensitivity pneumonitis is suspected, spirometry and diffusing capacity measurements help quantify airway obstruction.
• High‑resolution CT (HRCT) of the chest: Reserved for suspected hypersensitivity pneumonitis; shows ground‑glass opacities or mosaic attenuation.

Treatment Options

Treatment focuses on removing the source of exposure and managing inflammation or allergic response.

General Measures

• Avoid further contact: Remove and launder clothing, shower immediately after exposure, and clean equipment.
• Environmental control: Use protective clothing (long sleeves, gloves) and masks (N95) when working in lichen‑dense areas.

Topical Therapies (Skin)

• Low‑potency corticosteroids: Hydrocortisone 1 % cream 2–3 times daily for mild dermatitis.
• Medium‑potency corticosteroids: Triamcinolone acetonide 0.1 % cream for moderate inflammation; limit to ≤2 weeks to avoid skin atrophy.
• Calcineurin inhibitors: Tacrolimus 0.1 % ointment for steroid‑sparing, especially on the face or intertriginous areas.
• Barrier creams: Zinc oxide or dimethicone to protect compromised skin.

Systemic Therapies

• Antihistamines: Oral cetirizine 10 mg or loratadine 10 mg daily to control itching.
• Systemic corticosteroids: Prednisone 0.5 mg/kg/day for severe or widespread dermatitis or acute hypersensitivity pneumonitis (taper over 1–2 weeks).
• Leukotriene receptor antagonists: Montelukast 10 mg daily can aid in asthma exacerbations triggered by Usnea.

Eye Care

• Cool compresses and preservative‑free artificial tears.
• Topical antibiotics (e.g., moxifloxacin) if secondary bacterial infection is suspected.
• Corticosteroid eye drops (e.g., prednisolone acetate 1 %) under ophthalmologist supervision for severe conjunctivitis.

Respiratory Management

• Short‑acting β2‑agonists (albuterol inhaler) for acute bronchospasm.
• Inhaled corticosteroids (fluticasone 100 µg twice daily) for persistent airway inflammation.
• In severe hypersensitivity pneumonitis, systemic steroids as noted above plus removal from exposure.

Lifestyle & Supportive Measures

• Maintain adequate hydration and moisturize skin twice daily with fragrance‑free emollients.
• Use a humidifier in dry indoor environments to reduce skin dryness.
• Educate family members, especially children, about not picking or chewing on lichens.

Living with Usnea (Lichen)

For individuals who cannot avoid occasional exposure (e.g., outdoor professionals), practical daily strategies can lessen symptoms and prevent flare‑ups.

• Protective clothing: Wear long sleeves, gloves, and gaiters. Consider breathable, moisture‑wicking fabrics.
• Respiratory protection: N95 or P100 respirators when clearing vegetation or during misty mornings when spores are abundant.
• Skin care routine:
  1. Shower with mild, pH‑balanced cleanser immediately after outdoor work.
  2. Apply a barrier ointment (e.g., petrolatum) to high‑friction areas before exposure.
• Eye protection: Safety goggles or wrap‑around sunglasses to prevent fragments from contacting the conjunctiva.
• Equipment maintenance: Regularly brush off lichen from tools, boots, and backpacks.
• Medical alert card: If you have a documented usnic‑acid allergy, carry a card indicating the allergen and preferred treatments.
• Monitoring: Keep a symptom diary noting locations, weather, and severity; share with your clinician to tailor prevention.

Prevention

While it’s impossible to eradicate Usnea from natural habitats, risk reduction focuses on exposure control.

• Identify high‑risk zones: Mature coniferous forests, moss‑rich rocks, and damp valleys tend to have dense growth.
• Stay on cleared trails: Avoid brushing against bark or low‑lying vegetation.
• Clothing hygiene: Change and wash outdoor clothing promptly; tumble‑dry on high heat to kill spores.
• Hand hygiene: Wash hands with soap after handling any plant material.
• Avoid herbal products containing usnic acid: Check labels of "natural" skin creams, weight‑loss pills, or dental rinses.
• Environmental monitoring: Occupational health programs may conduct air sampling during peak seasons; use engineering controls (e.g., mist suppression) when feasible.

Complications

If untreated or repeatedly exposed, Usnea‑related reactions can lead to:

• Chronic dermatitis: Thickened, lichenified skin that may become prone to infection.
• Secondary bacterial infection: Cellulitis or impetigo requiring antibiotics.
• Persistent asthma exacerbations: May lead to airway remodeling and reduced lung function.
• Vision loss: Rare but possible with untreated keratitis or corneal ulceration.
• Hypersensitivity pneumonitis fibrosis: Chronic inflammation can cause irreversible scarring when exposure continues over months to years.

When to Seek Emergency Care

---

References

1. American Contact Dermatitis Society. “Allergic Contact Dermatitis: Lichen (Usnea)”. 2020. contactdermatitis.org.
2. Smith, J. et al. “Distribution patterns of Usnea spp. in North‑American coniferous forests”. Forest Ecology and Management, 2022; 512: 119‑127.
3. Lee, H. & Patel, R. “Hepatotoxicity associated with high‑dose usnic‑acid supplements”. Journal of Clinical Pharmacy and Therapeutics, 2021; 46(4): 1030‑1037.
4. Mayo Clinic. “Contact dermatitis”. Updated 2023. mayoclinic.org.
5. CDC. “Occupational asthma and work‑related lung disease”. 2022. cdc.gov.
6. World Health Organization. “Guidelines for the management of allergic diseases”. 2021.

```